* Staying flexible and transparent...
Though only a few weeks old, this post from early May outlines why I sold the cannabis gap (higher) on the rescheduling announcement. (Pay special attention to the May column).
And, why... on weakness I may reload:
Only a Few Good Men?
* More cannabis talk
* I am tough on dogmatic cannabis Perma Bulls who have experienced a decline in MSOS from $40 to $9 and still think they are right on the sector's outlook!
* There is little critical analysis and/or objectivity in their analysis of cannabis stocks...
"The definition of insanity is doing the same thing over and over and expecting different results."
- Albert Einstein
There is little critical analysis and/or objectivity in the analysis of cannabis stocks.
In the main, Perma Bulls, sell side analysts and "paid advisors" deliver the same (too optimistic) pablum week after week. - undaunted by their very wrong-footed evaluation of short- and intermediate- term industry fundamentals.
They are their own worst enemies and, often can't seem or don't want to handle the truth or an alternative view.
It is as if, deaf to their analytical and market shortcomings, the weakness in cannabis stocks are other people's "faults" - Washington, D.C. politicians (especially of a Senator Schumer-kind), naysayers/perma bears,lobby groups (SAM), and those simply opposed to weed use, etc.
Routine daily podcasts and recaps - by those blinded by their biased views - have become narrow and repetitive conversations of an insular (and bullish) cannabis community blinded by not only their lack of objectivity but also, as noted, by redundancy of view and the absence of critical analysis of uninspiring industry fundamentals and overrated longer term prospects.
The same observation applies to cannabis industry conventions and meetings - which I will no longer attend. Again, too much of a "love fest" and too little room for a serious exploration of the industry's challenges and headwinds.
Any critical analysis countered on Twitter or any other platform of social media is met with resistance (and "blocking") by a group of talking heads with no sense of ownership or, seemingly, conscience - as they have led retail lemmings off the cliff (as MSOS has dropped from $40 to $9).
See Albert Einstein's quote above!
Mid-week I offered some bonafide reasons why the upside, for now, is limited and why I took advantage of the swift rise to take profits:
BY DOUG KASS MAY 1, 2024 11:14 AM EDT
Why I Sold All of My Cannabis Holdings on Yesterday's Sharp Climb Higher
- Schedule III does not necessarily resolve uplisting issues.
- Schedule III does not resolve institutional ownership and custody issues.
- So, a further rally in cannabis stocks will be dependent on follow thru of interest by retail investors (who have been consistently burned by purchasing strength over the last 3-5 years).
- An excise tax may be instituted to offset the loss of tax revenues from the elimination of 280e.
- The notice/review/lawsuits issues during the estimated six month comment period could get contentious.
- If Schedule III is not finalized before year end there could be renewed concerns that a new Administration will try to turn back the decision.
- Some portion of the benefit of elimination of 280e may inure to the benefit of consumer (in terms of lower weed prices).
- The total addressable market for cannabis is materially less than consensus expectations.
- State silos create diseconomies of scale.
- State dispensary limitations in popular/large states is a headwind to consumer branding and market penetration opportunities.
- Accounting standards for the cannabis sector are aggressive/weak.
- Managements are still not ready for prime time players.- arguably, their operating and forecasting skills are not yet keenly developed.
- Accumulated debt and non payment of taxes represent a heavy load for companies not delivering returns anywhere near their cost of capital.
Position: None
BY DOUG KASS
MAY 1, 2024 10:15 AM EDT
Here is more support of one of my arguments, among other reasons, that the notice period over the remainder of 2024 will be contentious and could be drawn out:
Marijuana Legalization Opponents Raise Money For Potential Lawsuit Against Federal Rescheduling Move - Marijuana Moment
Bottom Line
I always speak my mind and I don't suffer fools who don't have investment process or whose analysis I believe to be miles long but only inches deep.
I try to anchor my views based on objective analysis and not hope or dogma.
Sometimes I fail in my own analysis but I try to be detailed and objective - to examine not only the positives but the negatives.
That said, I fully plan to return to cannabis equities at a point in which more objectivity (and lower share prices) return to the space and, more importantly, when the upside reward v downside risk warrants such a return.
As I noted in a column earlier this week, cannabis equities (in theory) have the same "open-ended" upside potential of some of the past, important market leaders (and "game changers"):
The Lesson From the 'Game Changers'
They are: Nvidia (NVDA) , Tesla (TSLA) , Lilly (LLY) , and Novo Nordisk (NVO) .
* The perception of near open-ended market opportunities invokes speculation/animal spirits that typically produce much higher stock prices.
* "Game changers" are different than "core compounders" — the former, at a moment in time, are seen to having the sky as the limit whereas the latter have durable, deep and long-lasting competitive moats.
Nvidia (in AI (artificial intelligence)), Tesla (electric vehicles) and Novo Nordisk/Eli Lilly (in GLP-1 drugs) are recent examples of equities that are perceived to be facing "open ended" end-market opportunities — and outsized sales/profits growth — for the foreseeable future.
These stocks are seen to face such promising relative and absolute profit growth that determining terminal price earnings multiples are difficult. And, more often than not, the exceptional growth prospects are accorded a high valuation that, arguably and inevitably, results in so much speculation that historic stock prices and multiples are thrown out the window and animal spirits propel the stocks to almost geometric expansion.
By means of background, I tend to be a value investor. But, at the same time, I realize how one can generate excess returns ("alpha") by committing a portion of my portfolio to more speculative issues with an "open ended" flavor.
Some of my recent buys in biotech, cannabis and on-line gaming have similar characteristics to some of the past winners and game changers named above — in that the upside has that "open ended" character and feeling to them:
* Biotech - Long runway for GLP-1 drugs (Viking Therapeutics (VKTX) )
* Cannabis - New states lead to rising market demand (Florida), rescheduling means elimination of 280-e taxation/, SAFR means uplifting/resolution of custody issues/institutional buying (MSO, Curaleaf (CURLF) , Terrascend (TSNDF), Green Thumb (GTBIF) and Trulieve (TCNNF) )
* On-Line Gaming - Vast market share and penetration opportunities (DraftKings (DKNG) )
BY DOUG KASS APR 30, 2024 10:00 AM EDT
As always, stay tuned...
Position: None
BY DOUG KASS
MAY 3, 2024 7:15 AM EDT